These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38616113)

  • 21. Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
    Zhang Y; Yuan M; Suo Y; Yang Q; Shao S; Li Y; Wang Y; Bao Q; Liu T; Li G
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):848-857. PubMed ID: 35596518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.
    Erdogan BR; Yesilyurt-Dirican ZE; Karaomerlioglu I; Muderrisoglu AE; Sevim K; Michel MC; Arioglu-Inan E
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
    Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats.
    Cheng ZJ; Vaskonen T; Tikkanen I; Nurminen K; Ruskoaho H; Vapaatalo H; Muller D; Park JK; Luft FC; Mervaala EM
    Hypertension; 2001 Feb; 37(2 Pt 2):433-9. PubMed ID: 11230314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
    Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
    J Atheroscler Thromb; 2020 Nov; 27(11):1141-1151. PubMed ID: 32101837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
    Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
    Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).
    Ayalasomayajula S; Han Y; Langenickel T; Malcolm K; Zhou W; Hanna I; Alexander N; Natrillo A; Goswami B; Hinder M; Sunkara G
    J Clin Pharm Ther; 2016 Aug; 41(4):424-31. PubMed ID: 27321165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model.
    Chiu HW; Wu CH; Lin WY; Wong WT; Tsai WC; Hsu HT; Ho CL; Cheng SM; Cheng CC; Yang SP; Li LH; Hua KF
    Inflammation; 2024 Apr; 47(2):696-717. PubMed ID: 38319541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
    Ge Q; Zhao L; Ren XM; Ye P; Hu ZY
    Exp Biol Med (Maywood); 2019 Sep; 244(12):1028-1039. PubMed ID: 31262190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LCZ696 ameliorates lipopolysaccharide-induced endothelial injury.
    Gao A; Wang Y; Gao X; Tian W
    Aging (Albany NY); 2021 Apr; 13(7):9582-9591. PubMed ID: 33839697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
    Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways.
    Khamis T; Alsemeh AE; Abdullah DM
    Sci Rep; 2022 Aug; 12(1):14654. PubMed ID: 36030321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.